Teva

J&J found liable in first opioid mis-marketing verdict

Oklahoma had also sued Teva Pharmaceuticals and Purdue Pharma, but both these companies agreed to settle out of court (for $85m and $270m respectively).

US politicians round on generics firms for blocking drug pricing probe

Renews focus on increases in generic drug prices. US politicians are going after Heritage Pharmaceuticals, Mylan and Teva Pharmaceutical Industries for allegedly stonewalling an earlier effort to gather drug pricing information. ... The lawsuit has led

AI is transforming pharma R&D – now it can transform pharma marketing

Early successes. In 2018 Teva created Braltusbot, a chatbot for HCPs on their UK Braltus website. ... Kim Innes, General Manager, Teva UK and Ireland said: “The experience for a worried HCP must be seamless.

Eli Lilly scores positive phase 3 results for Emgality in treatment resistant migraine

Emgality was approved in the US last September as a preventative treatment for migraine in adults, and became third in the market for this indication, following Amgen’s Aimovig and

Pfizer set to unveil Mylan merger and spin-off

Mylan’s share price has risen 30% in the last few days in expectation of an announcement, which will create a generics giant to rival market leader Teva in size. ... The merger is likely to have knock-on effects for the other big players in the market,

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]